N Engl J Med
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Abstract
Background
Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and a taxane.
Methods
We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody-drug conjugate) with those of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. The primary end point was progression-free survival (as determined by blinded independent central review); secondary end points included overall survival, objective response, and safety.
Results
Among 524 randomly assigned patients, the percentage of those who were alive without disease progression at 12 months was 75.8% (95% confidence interval [CI], 69.8 to 80.7) with trastuzumab deruxtecan and 34.1% (95% CI, 27.7 to 40.5) with trastuzumab emtansine (hazard ratio for progression or death from any cause, 0.28; 95% CI, 0.22 to 0.37; P<0.001). The percentage of patients who were alive at 12 months was 94.1% (95% CI, 90.3 to 96.4) with trastuzumab deruxtecan and 85.9% (95% CI, 80.9 to 89.7) with trastuzumab emtansine (hazard ratio for death, 0.55; 95% CI, 0.36 to 0.86; prespecified significance boundary not reached). An overall response (a complete or partial response) occurred in 79.7% (95% CI, 74.3 to 84.4) of the patients who received trastuzumab deruxtecan and in 34.2% (95% CI, 28.5 to 40.3) of those who received trastuzumab emtansine. The incidence of drug-related adverse events of any grade was 98.1% with trastuzumab deruxtecan and 86.6% with trastuzumab emtansine, and the incidence of drug-related adverse events of grade 3 or 4 was 45.1% and 39.8%, respectively. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 10.5% of the patients in the trastuzumab deruxtecan group and in 1.9% of those in the trastuzumab emtansine group; none of these events were of grade 4 or 5.
Conclusions
Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower among those who received trastuzumab deruxtecan than among those who received trastuzumab emtansine. Treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast03 ClinicalTrials.gov number, NCT03529110.).
Related Questions
Would you still offer trastuzumab deruxtecan in a patient with progressive HR+/HER2+ breast cancer who has prior history of cell cycle inhibitor related pneumonitis?
In DESTINY-Breast04, about 70% of patients were CDK4/6i treated but were excluded if they had a history of ILD/pneumonitis. So, we don't know if this patient is at higher risk of pneumonitis with trastuzumab deruxtecan. I would consider it if her previous pneumonitis was mild and fully resolved with...
How do you approach brain SRS for patients currently receiving Trastuzumab deruxtecan with progressive brain lesions?
Trastuzumab deruxtecan is an antibody drug conjugate targeting HER2 cells. This agent has recently been compared to a similar antibody drug conjugate T-DM1 (Kadcyla) and was found to improve disease progression and lower the risk of death for patients with relapsed HER2 metastatic breast cancer (Cor...
What are your top takeaways from SABCS 2022?
Here are my top 3 presentations (specifically for breast medical oncology) that I would say are most impactful (now or soon), with slides attached. GS3-04 - Capivasertib Phase III (CAPItello-291) Trial – these results will likely change standards for post CDKi progression for HR+/HER2-negative metas...
How would you treat a newly metastatic ER+ PR+ HER2+ triple positive breast cancer with diffuse symptomatic disease and severe neuropathy from prior adjuvant paclitaxel?
This is a challenging clinical situation where the medical oncologist has to balance the need to rapidly induce a response to relieve the patient's symptoms and the risk of exacerbating the patient's peripheral neuropathy, which may be irreversible. Because of the latter concern, I would avoid stand...
For a patient with well differentiated de novo triple positive metastatic breast cancer who did not respond to THP, do you sequence all available HER2 targeted options before endocrine therapy?
Endocrine combinations for triple positive breast cancer are honestly a bit understudied. We are starting to get more data in this space, SUMMIT, for example, neratinib + fulvestrant + trastuzumab. I think endocrine based combinations are very interesting and there are likely some tumors that are mo...
Do you continue endocrine therapy for women with HER2+/HR+ metastatic breast cancer when starting a HER2-directed antibody-drug-conjugate?
In general, no, I would not. I do think there is room for case-by-case evaluation in determining the right course of action for a particular patient, e.g., based on how strongly the patient's tumor seems driven by ER vs HER2, how they have historically responded to ER-directed vs HER2-directed thera...
What is trastuzumab deruxtecan's activity for patients with CNS+ disease?
The DESTINY-Breast04 trial excluded patients with active CNS metastases so the study does not provide information on the activity of this drug in HER2-low CNS disease. In HER2-positive disease, however, CNS activity has been observed with trastuzumab deruxtecan; among patients evaluated for CNS resp...
What are your top takeaways in Breast Cancer from ASCO 2022?
DESTINY-Breast04: it is phase III study of Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice in HER2-low metastatic breast cancer (MBC). This study showed improved progression-free survival (PFS) and overall survival (OS) with T-DXd vs standard therapy in this patient population. T-...
How would you approach a locally recurrent HER2 positive breast cancer patient previously treated with TCHP, lumpectomy, and a year of adjuvant TDM-1?
Assuming that the patient's metastatic work-up is negative, and that the local recurrence is in the breast, limited in volume and resectable, standard local management would be a mastectomy, without post-mastectomy radiation (as she presumably received radiation after her lumpectomy). I also assume ...
Are there strategies to mitigate the risk of developing ILD/pneumonitis while using trastuzumab deruxtecan?
The most important strategy is global awareness of ILD as a potentially serious complication that may initially present with subtle signs. Patients and all care team members must not only be aware but remind others in the patient/family care circle. This needs to be reinforced regularly. The recogni...
When, if ever, will you utilize T-DM1 in metastatic HER2+ breast cancer given trastuzumab deruxtecan's significantly improved efficacy vs T-DM1?
We now have very compelling data that trastuzumab deruxtecan (T-DXd) is highly effective in the second line setting and superior to T-DM1. The announcement of results came with the statement that "this study will lead to a paradigm shift in the treatment of Her2-positive metastatic breast cancer". S...
Would you use T-DXd or capecitabine/trastuzumab/tucatinib for HER2+ metastatic breast cancer with predominantly CNS progression after THP?
We now have long-term overall survival data from the DESTINY-Breast03 (DB03) trial, which further supports the efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer, including those with CNS metastases. However, my preference remains unchanged, favoring the HER2C...
How do you monitor for pulmonary toxicity for patients on trastuzumab deruxtecan?
Eligibility criteria for T-DXd trials were based on clinical history and not on objective findings such as PFTs or radiographic criteria. Therefore, risk for factors for T-DXd-related ILD or other pulmonary toxicity are not at all clear, although they may emerge with larger pooled safety analyses an...
What is the best second line treatment for a HER2+ metastatic breast cancer treated with frontline paclitaxel and anti-HER2 therapy?
I would use T-DM1 (ado trastuzumab emtansine) in this situation as a second line therapy. T-DM1 has a very favorable side effect profile. Pertuzumab added a survival benefit when combined docetaxel and trastuzumab (median of 15.7 months) though this was a first-line treatment (Swain et al. NEJM 2015...
When do you consider HER2-targeting antibody drug conjugates in the first line setting for metastatic HER2 positive, ER negative breast cancer?
This question cannot be answered for any specific situation with a high degree of reliability without a controlled clinical trial. In my opinion, there could be situations in which I would predict a favorable benefit/risk ratio to the use of T-DXd in first line as opposed to standard taxane + trastu...